These findings demonstrate that CAP mitigates HFD-induced hepatic inflammation through TRPV1 activation, thereby interrupting the second hit in MASLD pathogenesis and potentially preventing disease progression. The gene discussed is TRPV1; the disease is metabolic dysfunction-associated steatotic liver disease.